Supplementary Figure S8 from Phase I Study of SYNB1891, an Engineered E. coli Nissle Strain Expressing STING Agonist, with and without Atezolizumab in Advanced Malignancies
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Figure 8. Representative immunofluorescence images for patient 200-003 and 100-005.
Language: English
Topic: Bacterial Cancer Therapy
Subfield: Biotechnology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4378215518
Cites:
Cited by:
Related to:
